SRR2932840
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.630
- ALLOGRAFT_REJECTION+0.600
- INTERFERON_GAMMA_RESPONSE+0.560
- IL6_JAK_STAT3_SIGNALING+0.450
- COMPLEMENT+0.400
- INFLAMMATORY_RESPONSE+0.310
- APICAL_SURFACE+0.190
- IL2_STAT5_SIGNALING+0.190
- KRAS_SIGNALING_UP+0.110
- KRAS_SIGNALING_DN+0.020
Top 10 suppressed
- MYC_TARGETS_V2-0.600
- MYC_TARGETS_V1-0.540
- CHOLESTEROL_HOMEOSTASIS-0.450
- MTORC1_SIGNALING-0.450
- GLYCOLYSIS-0.410
- UNFOLDED_PROTEIN_RESPONSE-0.410
- G2M_CHECKPOINT-0.390
- HYPOXIA-0.380
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.370
- E2F_TARGETS-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | be8d8236-4ebc-46de-a4fd-a901fec1cdce | — | — | 0.932 |
| 2 | C3N-02920 | — | cohortA1 | 0.903 |
| 3 | SRR8518296 | — | A | 0.893 |
| 4 | 20050035.Her2HRneg | — | D | 0.884 |
| 5 | SRR8613700 | — | D | 0.877 |
| 6 | TCGA-44-2657-01A-01R-1107-07 | — | cohortA1 | 0.876 |
| 7 | SRR25617853 | — | D | 0.867 |
| 8 | SRR25043622 | — | — | 0.865 |
| 9 | MBCProject_1819_T2B_RNA | — | D | 0.865 |
| 10 | TCGA-AO-A0JC-01A-11R-A056-07 | — | D | 0.861 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.630 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.560 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.450 | Inavolisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.110 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.020 | Remibrutinib | — uncovered |
| COAGULATION | 0.010 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.010 | Cobimetinib | — uncovered |